Sponsored By

Indena, Phamatoka Agreement to Increase Cranberry Market

October 8, 2013

1 Min Read
Indena, Phamatoka Agreement to Increase Cranberry Market

MILAN, ItalyIndena entered an industrial and commercial agreement with Pharmatoka as part of a new strategic initiative to strengthen its presence in cranberry derivatives.

According to the agreement, Indena will produce GIKACRAN® under exclusive license for Pharmatoka and will directly market GIKACRAN® in Japan, South Korea, China, India and Russia.

GIKACRAN® is a well-characterized cranberry juice (Vaccinium macrocarpon) extract, standardized to provide 17 to 22 percent total proanthocyanidin (PAC) measured by dimethylaminocinnamaldehyde (DMAC) method. GIKACRAN® is a 200mg dosage that contains 36mg of cranberry proanthocyanidins (PACs), and provides the same amount of PACs found in 40g of fresh fruits.

"We are excited to start the commercialization of GIKACRAN® in these countries in which we have a historical important presence, and Japan is the first market we will approach," said Christian Artaria, marketing director, Indena.

GIKACRAN® has been used in different dietary supplement products in Europe under the brand names URELL® and ELLURA®. The product is also available in Malaysia as a traditional herbal medicine and in Australia as a complementary listed medicine.

Learn more about Indena and its research and development initiatives in the SupplySide R&D Insights Global Experience R & D Documentary Film.

Subscribe and receive the latest insights on the health and nutrition industry.
Join 37,000+ members. Yes, it's completely free.

You May Also Like